LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced the closing of an underwritten
registered public offering of 1,150,000 shares of its common stock at a
price to the public of $190.00 per share. The shares of common stock
issued in the offering included 150,000 shares of common stock issued
upon the exercise in full by the underwriters of their option to
purchase additional shares. The net proceedsmore...